331. Idiopathic multicentric castleman disease Clinical trials / Disease details


Clinical trials : 33 Drugs : 46 - (DrugBank : 25) / Drug target genes : 31 - Drug target pathways : 155

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-jRCT2071190029
25/05/202009/10/2019Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant)Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial (SPIRIT Compliant) idiopathic multicentric Castleman's disease
Castleman's disease
Treatment: Sirolimus 2 mg po once/day.
Control: Placebo given orally once daily
Kawakami AtsushiNULLNot Recruiting>= 18age oldNot applicableBoth20Phase 2Japan
2NCT01441063
(ClinicalTrials.gov)
September 13, 201124/9/2011Tocilizumab for KSHV-Associated Multicentric Castleman DiseasePilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associated Multicentric Castleman DiseaseCastleman Disease;Multicentric Castleman Disease;Giant Lymph Node HyperplasiaDrug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)National Cancer Institute (NCI)NULLCompleted18 YearsN/AAll8Phase 2United States
3NCT01183598
(ClinicalTrials.gov)
August 200613/8/2010A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra TreatmentProvision of Tocilizumab for Patients With Multicentric Castleman's Disease Who Have Demonstrated Benefit From Previous Tocilizumab TreatmentCastleman's DiseaseDrug: tocilizumab [RoActemra/Actemra]Hoffmann-La RocheNULLCompleted18 YearsN/ABoth3Phase 1United States